These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 16365461)

  • 1. SC5 mAb represents a unique tool for the detection of extracellular vimentin as a specific marker of Sezary cells.
    Huet D; Bagot M; Loyaux D; Capdevielle J; Conraux L; Ferrara P; Bensussan A; Marie-Cardine A
    J Immunol; 2006 Jan; 176(1):652-9. PubMed ID: 16365461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased expression of a novel early activation surface membrane receptor in cutaneous T cell lymphoma cells.
    Nikolova M; Tawab A; Marie-Cardine A; Bagot M; Boumsell L; Bensussan A
    J Invest Dermatol; 2001 May; 116(5):731-8. PubMed ID: 11348462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Significance of circulating T-cell clones in Sezary syndrome.
    Ortonne N; Huet D; Gaudez C; Marie-Cardine A; Schiavon V; Bagot M; Musette P; Bensussan A
    Blood; 2006 May; 107(10):4030-8. PubMed ID: 16418328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Epidermotropic T cell lymphomas as models for tumor progression].
    Bagot M; Bensussan A
    Med Sci (Paris); 2006 Feb; 22(2):192-6. PubMed ID: 16457762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD158k/KIR3DL2 is a new phenotypic marker of Sezary cells: relevance for the diagnosis and follow-up of Sezary syndrome.
    Poszepczynska-Guigné E; Schiavon V; D'Incan M; Echchakir H; Musette P; Ortonne N; Boumsell L; Moretta A; Bensussan A; Bagot M
    J Invest Dermatol; 2004 Mar; 122(3):820-3. PubMed ID: 15086570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD158K/KIR3DL2 transcript detection in lesional skin of patients with erythroderma is a tool for the diagnosis of Sézary syndrome.
    Ortonne N; Le Gouvello S; Mansour H; Poillet C; Martin N; Delfau-Larue MH; Leroy K; Farcet JP; Bagot M; Bensussan A
    J Invest Dermatol; 2008 Feb; 128(2):465-72. PubMed ID: 17703174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD164 identifies CD4
    Benoit BM; Jariwala N; O'Connor G; Oetjen LK; Whelan TM; Werth A; Troxel AB; Sicard H; Zhu L; Miller C; Takeshita J; McVicar DW; Kim BS; Rook AH; Wysocka M
    Arch Dermatol Res; 2017 Jan; 309(1):11-19. PubMed ID: 27766406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of cell surface molecules characterizing human cutaneous T-cell lymphomas.
    Nikolova M; Bagot M; Boumsell L; Bensussan A
    Leuk Lymphoma; 2002 Apr; 43(4):741-6. PubMed ID: 12153159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD158k is a reliable marker for diagnosis of Sézary syndrome and reveals an unprecedented heterogeneity of circulating malignant cells.
    Moins-Teisserenc H; Daubord M; Clave E; Douay C; Félix J; Marie-Cardine A; Ram-Wolff C; Maki G; Beldjord K; Homyrda L; Michel L; Bensussan A; Toubert A; Bagot M
    J Invest Dermatol; 2015 Jan; 135(1):247-257. PubMed ID: 25158034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of CD164 on Malignant T cells in Sézary Syndrome.
    Guenova E; Ignatova D; Chang YT; Contassot E; Mehra T; Saulite I; Navarini AA; Mitev V; Dummer R; Kazakov DV; French LE; Hoetzenecker W; Cozzio A
    Acta Derm Venereol; 2016 May; 96(4):464-7. PubMed ID: 26524186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engagement of ILT2/CD85j in Sézary syndrome cells inhibits their CD3/TCR signaling.
    Nikolova M; Musette P; Bagot M; Boumsell L; Bensussan A
    Blood; 2002 Aug; 100(3):1019-25. PubMed ID: 12130517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cell surface differentiation antigens of the malignant T cell in Sezary syndrome and mycosis fungoides.
    Haynes BF; Bunn P; Mann D; Thomas C; Eisenbarth GS; Minna J; Fauci AS
    J Clin Invest; 1981 Feb; 67(2):523-30. PubMed ID: 6970206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dysregulation of lymphocyte interleukin-12 receptor expression in Sézary syndrome.
    Zaki MH; Shane RB; Geng Y; Showe LC; Everetts SE; Presky DH; Wysocka M; Moore JS; Rook AH
    J Invest Dermatol; 2001 Jul; 117(1):119-27. PubMed ID: 11442758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression and function of the natural cytotoxicity receptor NKp46 on circulating malignant CD4+ T lymphocytes of Sézary syndrome patients.
    Bensussan A; Remtoula N; Sivori S; Bagot M; Moretta A; Marie-Cardine A
    J Invest Dermatol; 2011 Apr; 131(4):969-76. PubMed ID: 21191411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential expression of CD24-related epitopes in mycosis fungoides/Sézary syndrome: a potential marker for circulating Sézary cells.
    Pirruccello SJ; Lang MS
    Blood; 1990 Dec; 76(11):2343-7. PubMed ID: 1701668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD158k/KIR3DL2 is a useful marker for identifying neoplastic T-cells in Sézary syndrome by flow cytometry.
    Bahler DW; Hartung L; Hill S; Bowen GM; Vonderheid EC
    Cytometry B Clin Cytom; 2008 May; 74(3):156-62. PubMed ID: 18061949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The diagnosis of Sézary syndrome on peripheral blood by flow cytometry requires the use of multiple markers.
    Klemke CD; Brade J; Weckesser S; Sachse MM; Booken N; Neumaier M; Goerdt S; Nebe TC
    Br J Dermatol; 2008 Sep; 159(4):871-80. PubMed ID: 18652582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating clonal CLA(+) and CD4(+) T cells in Sezary syndrome express the skin-homing chemokine receptors CCR4 and CCR10 as well as the lymph node-homing chemokine receptor CCR7.
    Sokolowska-Wojdylo M; Wenzel J; Gaffal E; Lenz J; Speuser P; Erdmann S; Abuzahra F; Bowman E; Roszkiewicz J; Bieber T; Tüting T
    Br J Dermatol; 2005 Feb; 152(2):258-64. PubMed ID: 15727636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating natural killer lymphocytes are potential cytotoxic effectors against autologous malignant cells in sezary syndrome patients.
    Bouaziz JD; Ortonne N; Giustiniani J; Schiavon V; Huet D; Bagot M; Bensussan A
    J Invest Dermatol; 2005 Dec; 125(6):1273-8. PubMed ID: 16354199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sezary syndrome cells unlike normal circulating T lymphocytes fail to migrate following engagement of NT1 receptor.
    Magazin M; Poszepczynska-Guigné E; Bagot M; Boumsell L; Pruvost C; Chalon P; Culouscou JM; Ferrara P; Bensussan A
    J Invest Dermatol; 2004 Jan; 122(1):111-8. PubMed ID: 14962098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.